Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Prothena Corp (NQ: PRTA )

27.08 +0.88 (+3.36%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 20, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 331,757
Open 26.90
Bid (Size) 25.60 (2)
Ask (Size) 59.50 (1)
Prev. Close 26.20
Today's Range 25.73 - 27.33
52wk Range 23.82 - 79.75
Shares Outstanding 45,047,449
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
A Preview Of Prothena Corp's Earnings
Prothena Corp (NASDAQ:PRTA) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Prothena Corp... 
Via Benzinga

Performance

YTD
-44.98%
-44.98%
1 Month
-18.75%
-18.75%
3 Month
-20.70%
-20.70%
6 Month
-54.11%
-54.11%
1 Year
+8.10%
+8.10%

More News

Read More
Why RBC Capital Sees 'Multiple High-Risk' On This Neurology-Focused Stock
Via Benzinga
10 Biggest Price Target Changes For Monday
Via Benzinga
Prothena Highlinghts New Preclinical Data For Alzheimer's, Parkinson's Vaccine Programs
Via Benzinga
Recap: Prothena Corp Q4 Earnings
Via Benzinga
Prothena Receives FDA Fast Track Designation for PRX012 for the Treatment of Alzheimer's Disease
Via Benzinga
The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings
Via Benzinga
The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios
Via Benzinga
Earnings Scheduled For February 17, 2022
Via Benzinga
Analyst Ratings For Prothena Corp
Via Benzinga
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
Via Benzinga
Why Jim Cramer Prefers This Mining Stock Over Vale
Via Benzinga
The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact
Via Benzinga
4 Stocks Insiders Are Buying
Via Benzinga
50 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
28 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Mid-Morning Market Update: Markets Open Higher; US Inflation Rate Rises To 7% In December
Via Benzinga
Best Stocks Of 2021: Meme Stocks, Biotechs Highlight Broad Sector Strength
Via Investor's Business Daily
7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts
Via InvestorPlace
Exposures COVID-19
7 A-Rated Biotechs to Buy for the Long Run
Via InvestorPlace
Prothena Corp: Q3 Earnings Insights
Via Benzinga
7 A-Rated Healthcare Stocks to Buy for the Long Haul
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.